Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
NCT02839681 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2019-05-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to slow, insufficient accrual.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MSLN within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-05-15Results posted on the registry: Mayo Clinic, Anetumab Ravtansine + Atezolizumab (NCT03455556)
- 2020-03-17Results posted on the registry: Morphotek, Placebo + Amatuximab (NCT02357147)
- 2020-03-17Also stopped (terminated): Morphotek, Placebo + Amatuximab (NCT02357147)
- 2019-12-17Also stopped (terminated): National Cancer Institute (NCI), Amatuximab (MORab-009) (NCT01413451)
- 2019-11-22Results posted on the registry: National Cancer Institute (NCI), LMB-100 + SEL-110 (NCT03436732)
- 2019-11-22Also stopped (terminated): National Cancer Institute (NCI), LMB-100 + SEL-110 (NCT03436732)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision